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Introduction
　Periodontal disease is characterized by destruc-
tion of periodontium, alveolar bone loss and tooth 
exfoliation.  To repair damaged periodontal tissue, 
surgical periodontal therapies, including periodon-
tal regenerative therapy, are carried out.  One 
type of periodontal regenerative therapy is the use 
of enamel matrix derivative (EMD).  Periodontal 
surgery using EMD has been employed in clinical 
treatment to regenerate periodontal apparatus 
damaged by periodontal disease1-6.  EMD is pro-
duced from enamel matrix derived from mandibu-
lar premolars and molars of pigs7.  However, EMD 
therapy has two major disadvantages : the use of 
animal-derived preparations7 and the use of com-
plex proteins8-10, which carry risks of animal-to-
human transmission4 and antigenicity2,4,9,11,12, and 
raise issues regarding the effects of components of 
EMD.
　Based on our previous study8, an oligopeptide 
was synthesized artiﬁcially.  In our previous study, 
when 30 mg of EMD in 1 mL of propylene glycol 
was injected into the backs of rats, chondrogenesis 
was observed at 7 days after injection, with 
numerous eosinophilic round bodies (ERBs) 
around the formed cartilage tissue.  ERBs were 
examined in some pathological sections, microdis-
sected from the rat-back sections, and analyzed 
biochemically.  Brieﬂy, ERBs were pathologically 
found not to contain polysaccharide, amyloid 
or hemosiderin.  Biochemical analysis of ERBs 
 Received 8/25/09 ; revised 12/9/09 ; accepted 12/26/09.
 Grant support : Grant-in-aid (18592273) to Akio Tanaka from 
the Ministry of Education, Science, and Sports of Japan and MEXT. 
HAITEKU (2007-2011).
 Requests for reprints : Kazuya Tominaga, Department of Oral 
Pathology, Osaka Dental University, 8-1 Kuzuhahanazono-cho, 
Hirakata-shi, Osaka 573-1121, Japan, Phone: ＋81-72-864-3057, 
Fax: ＋81-72-864-3157
Oral Science International, May 2010, p.26-36
Copyright © 2010, Japanese Stomatology Society. All Rights Reserved.
Tissue Reaction to Synthetic Oligopeptide Derived  
from Enamel Matrix Derivative in Rats
Tomoaki Hida, Kazuya Tominaga and Akio Tanaka
Department of Oral Pathology, Osaka Dental University
Abstract : Background : Enamel matrix derivative placed in the backs of rats induces numerous 
eosinophilic round bodies (ERBs) and hard tissue.  ERBs were analyzed by matrix assisted laser 
desorption ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) and by database analy-
sis.  Subsequently, a seven-amino-acid sequence was identiﬁed, and an artiﬁcial oligopeptide was 
synthesized with its sequence.  The present experiment was carried out to clarify whether or not 
the peptide induces hard tissue formation in vivo.
　Methods : Synthetic oligopeptide was injected into the backs of 15 rats.  After injection, the tis-
sues were excised at various times and prepared for light and immune-light microscopy.
　Results : A white lump was macroscopically observed in each rat back 14 days after injection of 
7.5 and 15 mg/mL synthetic oligopeptide, and endochondral ossiﬁcation and bone formation were 
microscopically observed in one rat back 14 days after injection of 15 mg/mL synthetic oligopeptide.
　Conclusions : The synthetic oligopeptide is pure, 1,118 dalton, and apparently low-toxicity.  It 
seems to produce hard tissues, such as cartilage and bone tissue.
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revealed a 40-kilodalton band, which band-protein 
did not include EMD8.  A seven-amino-acid 
sequence was identiﬁed by analyzing ERBs with 
matrix assisted laser desorption ionization time-
of-ﬂight mass spectrometry (MALDI-TOF MS) 
and database analysis.  The seven-amino-acid 
sequence is a part of amelogenin-exon 5.
　As EMD is a mixture, and includes proteins of 
various molecular weights8-10, EMD has antigenic-
ity2,9.  There have been no reports, however, of 
adverse effects in humans1,2,9,12, and it is reported 
that second surgery using EMD produces superior 
effects1.  It is generally accepted as essential that 
a peptide has a length of greater than approxi-
mately 10 residues13 or over 5 kilodaltons11 to 
function as an immunogen.  Our peptide is pure, 
only seven amino acids, and 1,118 dalton, and 
there is very little risk of producing an antibody.
　In the present study, in order to clarify the 
effect of the seven-amino-acid sequence, WYQN-
MIR, in vivo, the backs of rats were pathologically 
observed at various times after injection of the 
synthetic oligopeptide at various concentrations.
Materials and Methods
Preparation of synthetic oligopeptide and 
injection into the backs of rats
　Oligopeptide composed of seven amino acids, 
WYQNMIR8, was artiﬁcially synthesized by the 
manufacturer, as indicated in the previous 
report14.  The peptide solution was prepared at the 
concentrations of 0.0 (as the control), 0.3, 3.0, 7.5, 
15.0 and 30.0 mg/mL in glacial distilled water. 
These peptide solutions were mixed with 40 mg of 
alginate impression material for clinical dental 
use (Nissin, Kyoto, Japan) as scaffold15, which was 
injected with 0.3 mL of the solution into the 15 
backs of rats.  The rats were euthanized on days 1, 
3, 5, 7, and 14 (n = 3, for each day) after injection, 
and the backs of the rats were excised. The 
excised tissues were ﬁxed in 10% neutral buffered 
formalin ﬁxative for one day.  The protocol for the 
animal experiment was approved by the Animal 
Research Committee of Osaka Dental University 
(07-02029 and 08-02026).
Sectioning and staining
　Formalin-fixed, paraffin-embedded sections 
from each rat back were cut at 5-μm thickness 
and stained with hematoxylin-eosin (HE), toluid-
ine blue (TB), periodic acid/Schiff (PAS) reaction, 
Masson trichrome (MT), phosphotungstic acid-
hematoxylin (PTAH), and von Kossa's methods 
(VK) for special stainings. Sections were also 
stained immunohistochemically with anti-type III 
collagen (Chemicon, California, USA) and von-
Willebrand factor (factor VIII-related antigen ;  
DaKoCytomation, Glostrup, Denmark) rabbit 
serum diluted at 1 : 400 and 1 : 1,000, respectively. 
The EnVision+ System16 (DaKoCytomation, 
Glostrup, Denmark) was used to detect each anti-
gen-antibody complex.
Results
　Alginate impression materials, eosinophilic 
amorphous substances, mucous substrates and 
many neutrophils were observed in the rat backs 
at 1 day after injection of all concentrations of 
synthetic oligopeptide.
　There were numerous clusters of alginate 
impression materials intermingled with neutro-
phils in the rat backs at 3 days after injection. 
Macrophages, lymphocytes and plasma cells had 
inﬁltrated around the clusters of alginate impres-
sion materials. ERB-like substances that had 
formed were investigated at 3 days after injection 
at 7.5 mg/mL- and 30 mg/mL-concentration (Fig. 
1a) ;  they were stained purple by MT and orange 
to purple by PTAH, but they were not stained with 
TB (Fig. 1b).  Amorphous ERB-like substances 
were observed at 5 days after injection at 7.5 mg/
mL-concentration (Fig. 2a).  Some giant cell for-
mation was seen at 5 days after injection at 30 
mg/mL-concentration (Fig. 3).  The clusters of 
alginate impression material were negative for 
VK (Fig. 2b).  Sparse clusters of alginate impres-
sion materials were observed at 7 days (Fig. 4) 
or later after injection.
　Many eosinophils and foreign body giant cells, 
but few neutrophils, were observed at 14 days 
after injection at 0.0 mg/mL-concentration (Fig. 
5a).  There were abundant capillary blood vessels 
and giant cells at 14 days after injection at 0.3 mg/
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mL-concentration (Fig. 5b).  At 14 days after 
injection at 7.5 mg/mL- and 15 mg/mL-concentra-
tion we observed a lump (Fig. 6 and Table 1), com-
posed of two different types of tissue, in each of 
the three rat backs.  One type was a mucoid 
region (Fig. 7a), and the other type was a high cel-
lularity region.  Numerous tiny calciﬁcation-like 
substances were observed in the mucoid region, 
and many giant cells in the high cellularity region. 
Slight metachromasia was observed in the mucoid 
region in the sections stained with TB (Fig. 7b), 
but the same region of the serial sections was not 
stained with MT.  It was stained slightly brown 
with PTAH. Numerous tiny calciﬁcation-like sub-
stances in the mucoid region were stained black 
with VK (Fig. 7c), light blue with TB, PAS and 
MT, and brown to light purple with PTAH (Fig. 
7d).  In addition, they were slightly immunohis-
tochemically positive for type III collagen.  Endo-
chondral ossiﬁcation and bone formation were 
observed in one of the three rat backs at 14 days 
(Fig. 8a) after 15 mg/mL synthetic oligopeptide 
injection.  Cartilage showed metachromasia on 
staining with TB (Fig. 8b).  The cartilage was 
stained purple with PAS (Fig. 8c), light blue with 
MT (Fig. 8d), and brown with PTAH, and was 
immunohistochemically positive for type III colla-
gen near bone tissue (Fig. 9a).  Bone was stained 
light blue with TB (Fig. 8b), purple with PAS 
(Fig. 8c), and orange with MT (Fig. 8d) and 
PTAH, and was slightly immunohistochemically 
positive for type III collagen (Fig. 9b).  Capillary 
blood vessels around the bone were stained 
immnohistochemically positive for factor VIII-
related antigen (Fig. 10a).  There were no capil-
lary blood vessels in cartilage (Fig. 10b).  On the 
other specimens which did not show bone forma-
tion, acid mucopolysaccharide material was 
observed, which was stained with TB (Fig. 11).
Discussion
　The sequence of the synthetic oligopeptide is a 
part of amelogenin-exon 5 8, and a part of the 
N-terminal region of amelogenin17.  The sequence 
of N-terminal amelogenin shows a high level of 
conservation among human, bovine, and porcine 
moieties.  The ﬁrst three residues of the sequence 
of the synthetic oligopeptide show a striking 
degree of conservation of structure18.  Such conser-
vation might signify that it plays an important 
biological role.
　The N-terminal amelogenin stimulates osteocal-
cin expression of mesenchymal progenitor cells in 
vitro, and increases the cell number and induces 
osteopontin in pulp, in vivo19.  Full-length amelo-
genin molecules are shown to stimulate autocrinal 
BMP production, whereas the smaller amelogenin 
fragments, such as leucine-rich amelogenin pep-
tide (LRAP)- and tyrosine-rich amelogenin peptide 
(TRAP)-related molecules, stimulate autocrinal 
TGF-Beta production20. The molecular size of 
nascent amelogenin is diminished by matrix 
proteases in enamel biomineralization20.  Some 
smaller amelogenin becomes soluble, and is 
released from the insoluble amelogenin assem-
blies20.  ERBs derived from EMD8 might be made 
through amelogenin self-assembly.  ERB-like sub-
stances were examined 3 days after injection of 
synthetic peptide into the subcutaneous tissues of 
rat backs.  Whereas many ERBs were induced by 
EMD8, only a few ERB-like substances formed 
from the small peptide.  We think that the small 
peptide is directly related to chondrogenesis and 
osteogenesis, and we are now researching the 
effect of the small peptide on some types of cells in 
vitro.  ERB-like substances are made of synthetic 
oligopeptides which are soluble.  The staining 
results of ERB-like substances for TB, MT, PTAH, 
and PAS in the excised tissues are similar to those 
of the original ERBs.
　Human periodontal ligament ﬁbroblasts increase 
the expression of genes such as those for bone 
morphogenetic protein (BMP) receptor type IA, 
Table 1　Detection of hard tissue after injection in rat backs
Days after injection in rat backs
Concentration (mg/mL) 1 3 5 7 14
0.0 (control) － － － － －
0.3 － － － － －
3.0 － － － － －
7.5 － － － － ＋
15.0 － － － － ＋
30.0 － － － － －
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BMP4, osteonectin, and BMP receptor type IB, but 
decrease the expression of ﬁbroblast growth factor 
receptor-like protein 1 gene due to the effect of the 
synthetic peptide (our previous data)14.  In this 
study, numerous tiny calciﬁcation-like substances, 
cartilage and bone tissue were formed by 14 days 
after injection.  The results of special stainings 
showed that both cartilage and bone tissue were 
composed of polysaccharide matrix, but that 
numerous tiny calciﬁcation-like substances did 
not contain much polysaccharide matrix.  The 
stainability of the mucoid region, comprising the 
background of tiny calciﬁcation-like substances, 
was similar to that of cartilage.  Amelogenin or a 
part of amelogenin might induce mesenchymal 
cells to differentiate to cementoblasts or osteo-
blasts, and produce cementum or bone tissue.
　Next we must consider the scaffold.  Propylene 
glycol is pharmaceutically used as a solvent21. 
When propylene glycol was used as a scaffold of 
the synthetic oligopeptide, the mixture of the pro-
pylene glycol and the synthetic oligopeptide disap-
peared from the rat backs within 14 days after 
injection.  The injection into rat backs at the con-
centration of 30 mg of oligopeptide in one mL of 
propylene glycol produced resulted in a few ERB-
like substances after 5 days.  However, both oligo-
peptide and ERB-like substances disappeared 
from rat backs after 7 days or later (data not 
shown).  Synthetic oligopeptide in propylene glycol 
might be absorbed easier in rat backs.  Forty mg 
of alginate impression material for clinical dental 
use was applied as a scaffold for the synthetic oli-
gopeptide in the present study.  The alginate 
impression material is used as a slow-release scaf-
fold of N-methylnitrosourea in vivo15.  Whereas 
125 mg of alginate impression material paste, 
which Hamamoto et al. used as a scaffold15, 
remained macroscopically in rat backs for 8 weeks 
after injection, 40 mg of alginate impression mate-
rial paste disappeared almost entirely from rat 
backs (data not shown).
　In conclusion, the synthetic oligopeptide with an 
extended-release scaffold seems to produce hard 
tissues, such as cartilage and bone tissue.
　Amelogenin increases bone-sialoprotein (BSP) 
expression in normal osteoprogenitor cells22. 
Cementoblasts lining the tooth root surface 
express BSP and osteocalcin, but periodontal liga-
ment cells do not express these markers23.  In 
future research we intend to stain sections immu-
nohistochemically with anti-BSP, osteocalcin, and 
type I and type II collagen.
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Fig. 1　 In rats injected with 30 mg/mL-
concentration of synthetic peptide, 
eosinophilic round body (ERB)-like 
substances (arrows) are formed in the 
back at 3 days after injection. Some 
lumps of alginate impression materials 
(arrow heads) are occasionally observed 
near ERB-like substances (a: hematoxylin 
and eosin stain; b : toluidine blue stain; 
original mag. × 1).
(Bar : 1 mm)
Fig. 2　 ERB-like substances (arrows) are formed 
in the backs of rats 5 days after injection 
in rats injected with 7.5 mg/mL-
concentration of synthetic peptide. Some 
lumps of alginate impression materials 
(arrow heads) are observed around ERB-
like substances (a : hematoxylin and eosin 
stain; b : von Kossa stain; original mag. 
× 5).
(Bar : 0.1 mm)
Fig. 3　 Sections from the backs of rats injected with 30 mg/mL-concentration of synthetic 
peptide. Some lumps of alginate impression materials (arrow heads) and some gi-
ant cells (white arrow heads) are observed in the backs of rats 5 days after injec-
tion. (a : hematoxylin and eosin stain ;  original mag. × 5).
(Bar : 0.1 mm)
Fig. 4　 Histological ﬁndings from the backs of rats injected with 30 mg/mL-concentration 
of synthetic peptide. Some lumps of alginate impression materials (arrow heads) 
and some giant cells (white arrow heads) are observed in the backs of rats 7 days 
after injection. (a : hematoxylin and eosin stain; original mag. × 5).
(Bar : 0.1 mm)
Fig. 5　 In rats injected with 0 mg (control) (a) or 
0.3 mg (b)/mL-concentration of synthetic 
peptide, some lumps of alginate impres-
sion materials (arrow heads) are ob-
served in the backs of rats 14 days after 
injection. (a and b: hematoxylin and eosin 
stain ;  original mag. × 5).
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Fig. 6　 The backs of rats injected with 7.5 mg/mL-concentration of synthetic peptide. 
White lumps are observed in rat backs 14 days after injection.
Fig. 7　 Histological ﬁndings from the backs of 
rats injected with 7.5 mg/mL-concentra-
tion of synthetic peptide. Two different 
types of tissue, a mucoid region and a 
high cellularity region, are observed in 
rat backs 14 days after injection. There 
are numerous tiny calciﬁcation-like sub-
stances in the mucoid region (a : hema-
toxylin and eosin stain). They are 
stained black with VK (c) and brown to 
light purple with PTAH (d). The mucoid 
region is slightly stained, and some 
lumps of alginate impression material 
are stained purple with toluidine blue 
(b). (a-d ;  original mag. × 1).
(Bar : 1 mm)
Fig. 8　 Endochondral ossiﬁcation and bone for-
mation are observed in the backs of rats 
14 days after injection in rats injected 
with 15 mg/mL-concentration of synthet-
ic peptide (a : hematoxylin and eosin 
stain). Metachromasia is demonstrated 
at cartilage tissue with toluidine blue (b). 
Both cartilage and bone tissue are posi-
tive for PAS (c), but negative for Masson 
trichrome (d). (a-d ;  original mag. × 5).
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Fig. 9　 A section immunohistochemically stained 
with type III collagen (a ;  original mag. 
× 5) and a high magniﬁcation of 9a (b ;  
original mag. × 10) were obtained 14 
days after injection in rats injected with 
15 mg/mL-concentration of synthetic oli-
gopeptide.
(Bar : 0.1 mm)
Fig. 10　 In rats injected with 15 mg/mL-concen-
tration of synthetic oligopeptide, a sec-
tion immunohistochemically stained 
with factor VIII-related antigen (a and 
b ;  original mag. × 10) was obtained 14 
days after injection.
(Bar : 0.1 mm)
Fig. 11　 Sections from the backs of rats injected with 15 mg/mL-concentration of synthetic 
peptide. Endochondral ossiﬁcation and bone formation are not observed in rat 
backs 14 days after injection. There are some lumps stained purple with toluidine 
blue in the mucoid region. (original mag. × 1).
(Bar : 1 mm)
9a
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